Biopharmaceutical company MapLight Therapeutics applies for a U.S. IPO aiming to raise up to $100 million
Biotechnology company MapLight Therapeutics submitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) last Friday, planning to raise up to $100 million. The company focuses on therapies for neuropsychiatric disorders and central nervous system diseases, with its core candidate drug ML-007C-MA currently undergoing two Phase 2 clinical trials. MapLight plans to list on NASDAQ under the ticker symbol MPLT, with joint lead underwriters including Morgan Stanley
According to Zhitong Finance APP, MapLight Therapeutics (MPLT.US), a biotechnology company focused on developing therapies for neuropsychiatric disorders and central nervous system (CNS) diseases, which is currently in Phase 2 clinical trials, submitted an application to the U.S. Securities and Exchange Commission (SEC) last Friday to raise up to $100 million through an initial public offering (IPO).
MapLight's core candidate drug is ML-007C-MA, a fixed-dose combination formulation made from M1/M4 muscarinic receptor agonists and peripheral acting anticholinergic drugs, initially developed for the treatment of schizophrenia and Alzheimer's disease psychosis (ADP). Currently, the company is conducting two Phase 2 clinical trials for ML-007C-MA: one for the treatment of schizophrenia, with top-line data expected to be released in the second half of 2026; the other for the treatment of Alzheimer's disease psychosis, with top-line data expected to be released in the second half of 2027.
Founded in 2018 and headquartered in Redwood City, California, the company plans to list on the NASDAQ stock exchange under the ticker symbol MPLT. MapLight Therapeutics submitted a confidential IPO application on March 8, 2024. The joint lead underwriters for this offering are Morgan Stanley, Jefferies, Leerink Partners, and Stifel, and the company has not yet disclosed the pricing terms for the offering
